MEDIGEN, INC.

Home

Medigen, Inc. is a preclinical biomedical company that specializes in the development of safe and effective vaccines for emerging infectious diseases and cancer.

We develop our vaccines by using novel vaccine technologies such as virus-like particles (VLPs) and genetic vectors. Medigen also develops new ways of vaccine delivery for effective and safe immunization.

What We Do

Medigen, Inc. conducts scientific research and vaccine development in the areas of infectious diseases and cancer. Medigen scientists are the leading experts in these areas.

We developed unique platform technologies for vaccination against infectious diseases and cancer. These platform technologies are applicable to the vaccine development against many diseases that affect millions of people in the U.S. and worldwide.

We provide our customers with expert contract research services, including experiment design, intellectual property development, and publishing and presenting data to the scientific community and government agencies. Our expertise includes production of viruses and virus-like particles, characterization of VLPs and purification of VLPs. Contact us for further details or request a quote at

10/06/2015 Medigen presents Quadri-subtype virus-Like particle (VLP) design at the international meeting "Infuenza Vaccines for the World" in Albufeira, Portugal.

10/05/2015 Scientists from Medigen and the University of Maryland, Baltimore publish collaborative research on prostate cancer vaccine in the Vaccine.

09/12/2015 Collaborative study between Medigen, NIH and CDC reserachers "Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus" is published in the Vaccine.

09/14/2014 Article "Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice" is published in Vaccine by Medigen in collaboration with the University of Louisville (UofL), KY.

08/02/2014 Medigen and the University of Louisville collaborate on the development of replicon-based VLPV vaccine for Lassa fever.

07/28/2014 Medigen in collaboration with UTMB and UofL presents positive preclinical results with proprietary iDNA vaccines for alphaviruses including VEE and Chikungunya at the International Congress of Virology, Montreal, Canada.

06/21/2014 Medigen in collaboration with UTMB and UofL presents positive preclinical results on novel iDNA vaccines for VEE and Chikungunya viruses at the American Society for Virology meeting, Fort Collins, CO.

06/15/2014 Article "DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice" is published in the Journal of Infectious Diseases by Medigen in collaboration with the University of Texas Medical Branch (UTMB), Galveston, TX.

04/08/2014 Medigen receives U.S. Patent 8,691,563"IDNA vaccines and methods for using the same"

04/07/2014 Medigen and the University of Maryland, Baltimore (UMB) present positive preclinical results on replicon-based VLPV vaccine against prostate cancer at the American Association for Cancer Research meeting, San Diego, CA.

03/05/2014 Medigen, Inc. and KempBio, Inc. present results of influenza research at the International Society for BioProcess Technology, Washington, DC.

We've adviced members of scientific community and government agencies in the areas of vaccines for human immunodeficiency virus (HIV), influenza virus, hepatitis B virus (HBV), as well as for biodefence-relevant agents such as anthrax, Ebola, and Marburg viruses.